ClinicalTrials.gg
CompletedNCT04075513inRangeUpdated Nov 14, 2022Results posted

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

A Phase 4 interventional study of Insulin glargine, 300 U/ml and Insulin degludec, 100U/ml in Type 1 Diabetes Mellitus, sponsored by Sanofi. Completed at 7 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-11-14.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.

Enrollment
11th of 66
343 · median 73
Started
2019
with 1 other
Phase 4
24 of 66
none open now
Registered
57th of 66
by date
Lead sponsor
24 of 66
Sanofi

Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 11th largest by enrollment, is one of 2 that started in 2019, is one of 24 in phase 4, and was the 57th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

Primary Objective:

To demonstrate the non-inferiority of insulin glargine 300 units per milliliter (U/ml) in comparison to insulin degludec 100 U/ml on glycemic control and variability in participants with diabetes mellitus.

Secondary Objective:

To evaluate the glycemic control and variability parameters in each treatment group at Week 12 using Continuous Glucose Monitoring.

To evaluate the safety of insulin glargine 300 U/ml in comparison to insulin degludec 100 U/ml.

Read the detailed description

The duration of the study per participant was around 18 weeks: 1 or 2 weeks of screening followed by a 4-week run-in period, a 12-week treatment period and a 2 to 4 days follow-up period.

03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with Type 1 Diabetes mellitus.
  • Participants treated with multiple daily injections using basal insulin analog once daily and rapid acting insulin analogs for at least one year.
  • greater than or equal to (>=) 7 percent (%) (53 millimoles per mole [mmol/mol]) and less than or equal to (\<=) 10% (86 mmol/mol) at screening.

Exclusion criteria

Exclusion criteria:

  • Participants not on stable dose of basal insulin analog.
  • Participants having received Toujeo or Tresiba as basal insulin within 30 days prior to screening.
  • Participants not having used the same insulins (both basal and rapid) within 30 days prior to screening.
  • Participants having received basal insulin dose >= 0.6 units per kilogram body weight within 30 days prior to screening.
  • Participants having received any glucose lowering drugs (including any premixed insulins, human regular insulin as mealtime insulins, any others injectable or oral), other than basal and rapid insulin analogs, within 3 months prior to screening.
  • End stage renal disease or on renal replacement treatment.
  • Retinopathy or maculopathy with one of the following treatments, either recent (within 3 months prior to screening) or planned: intravitreal injections or laser or vitrectomy surgery.
  • Body weight change >=5 kilogram within 3 months prior to screening.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
343 participants (actual)

Study arms

  • Experimental
    Toujeo

    Toujeo (Insulin Glargine, 300 U/ml) subcutaneous (SC) injection, once daily in the morning before breakfast for 12 weeks on top of rapid acting insulin analog.

    Drug: Insulin glargine, 300 U/ml · Drug: Background therapy: Rapid acting insulin analogs

  • Active comparator
    Tresiba

    Tresiba (Insulin Degludec, 100U/ml) SC injection, once daily in the morning before breakfast for 12 weeks on top of rapid acting insulin analog.

    Drug: Insulin degludec, 100U/ml · Drug: Background therapy: Rapid acting insulin analogs

Interventions

  • DrugInsulin glargine, 300 U/ml

    Drug page: Insulin Glargine

    Pharmaceutical form: solution for injection in a prefilled pen Route of administration: SC injection

    Also known as: Toujeo, HOE901-U300

  • DrugInsulin degludec, 100U/ml

    Drug page: Insulin degludec

    Pharmaceutical form: solution for injection in a prefilled pen Route of administration: SC injection

    Also known as: Tresiba

  • DrugBackground therapy: Rapid acting insulin analogs

    Route of administration: SC injection

06

What researchers measure

Primary outcomes

  1. Percentage of Time of Glucose Concentration Within the Target Range of Greater Than or Equal to (>=) 70 to Less Than or Equal to (<=) 180 Milligrams Per Deciliter: Non-inferiority Analysis

    The Continuous Glucose Monitoring (CGM) system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. Adjusted least square (LS) means and standard error (SE) were obtained using analysis of covariance (ANCOVA) model on data obtained from the multiple imputations during Week 10 to Week 12.

    Time frame: During Week 10 up to Week 12

Secondary outcomes

  1. Glucose Total Coefficient of Variation (CV%)

    CV% was a measure of spread of variability relative to mean of population. For CGM glucose values, CV% was measure of glycemic variability across 20 days and calculated as ratio of standard deviation of glucose values to mean of glucose values. LS means and SE were obtained using ANCOVA model using fixed categorical effects of treatment groups (Toujeo, Tresiba), randomization stratum of screening HbA1c (\<8.0% versus \>=8.0%), and the continuous fixed covariate of Baseline value.

    Time frame: During Week 10 up to Week 12

  2. Percentage of Time of Glucose Concentration Within the Target Range of >=70 to <=180 Milligrams Per Deciliter: Superiority Analysis

    The CGM system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. Adjusted LS means and SE were obtained using ANCOVA model on data obtained from the multiple imputations during Week 10 to Week 12.

    Time frame: During Week 10 up to Week 12

  3. Glucose Within-day CV% and Between-day CV%

    CV% was a measure of spread of variability relative to mean of population. For CGM glucose values, CV% was measure of glycemic variability across 20 days and calculated within day and between days as ratio of standard deviation of glucose values to mean of glucose values. LS mean and SE were obtained from ANCOVA model including fixed categorical effects of treatment groups (TOUJEO, TRESIBA), randomization stratum of screening HbA1c (\<8.0% versus \>=8.0%), and as well as, the continuous fixed covariate of Baseline value.

    Time frame: During Week 10 up to Week 12

  4. Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 12

    Change in HbA1c at Week 12 was analyzed using an ANCOVA model including the fixed categorical effects of treatment groups (Toujeo, Tresiba), and the continuous fixed covariate of Baseline HbA1c value.

    Time frame: Baseline, Week 12

  5. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12

    Change in FPG was analyzed using an ANCOVA model including the fixed categorical effects of treatment groups (Toujeo, Tresiba) and the randomization stratum of HbA1c at screening (\<8.0%, \>=8.0%) and the continuous fixed covariate of Baseline FPG value.

    Time frame: Baseline, Week 12

  6. Percentage of Time With Glucose Level <70 Milligrams Per Deciliter (All Time and During the Night)

    The CGM system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. "All time" represent the time between 00.00 hour to 23.59 hours and "night" represent the time between 00.00 hour to 05.59 hours. LS means and SE were obtained using ANCOVA model using fixed categorical effects of treatment groups (Toujeo, Tresiba), randomization stratum of screening HbA1c (\<8.0% versus \>=8.0%), and the continuous fixed covariate of Baseline value.

    Time frame: During Week 10 up to Week 12

  7. Mean Hours Per Day With Glucose Level <70 Milligrams Per Deciliter (All Time and During the Night)

    "All time" represent the time between 00.00 hour to 23.59 hours and "night" represent the time between 00.00 hour to 05.59 hours. Mean hours per day with glucose level \<70 milligrams per deciliter during "all time" and only "during night" for the duration of Week 10 to Week 12 is reported in this outcome measure.

    Time frame: During Week 10 up to Week 12

  8. Percentage of Time With Glucose Level >180 Milligrams Per Deciliter

    The CGM system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. LS means and SE were obtained using ANCOVA model using fixed categorical effects of treatment groups (Toujeo, Tresiba), randomization stratum of screening HbA1c (\<8.0% versus \>=8.0%), and the continuous fixed covariate of Baseline value.

    Time frame: During Week 10 up to Week 12

  9. Mean Hours Per Day With Glucose Level >180 Milligrams Per Deciliter

    Mean hours per day with glucose level \>180 milligrams per deciliter for the duration of Week 10 to Week 12 is reported in this outcome measure.

    Time frame: During Week 10 up to Week 12

  10. Number of Participants With at Least One Hypoglycemic Event During the On-treatment Period

    Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions, because the participant was not capable of helping self. Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<3.9 millimoles per liter (mmol/L) (\<70 milligrams per deciliter). On-treatment period was defined as the time from the first injection of IMP (included) up to 2 days after the last injection of IMP.

    Time frame: From the first injection of IMP up to 2 days after the last injection of IMP (i.e., up to 86 days)

  11. Number of Hypoglycemic Events Per Participant Year During the On-treatment Period

    Number of hypoglycemia events (any, severe and documented) per participant-year of exposure were reported. Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions, because the participant was not capable of helping self. Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<3.9 mmol/L (\<70 milligrams per deciliter). On-treatment period was defined as the time from the first injection of IMP (included) up to 2 days after the last injection of IMP. Total participant years = The sum of the duration of exposure for all participants, expressed in participant years.

    Time frame: From the first injection of IMP up to 2 days after the last injection of IMP (i.e., up to 86 days)

07

Results

Posted Nov 14, 2022

Participant flow

The study was conducted at 40 active sites in 7 countries. A total of 550 participants were screened between 09 October 2019 and 06 May 2021, of which 343 participants were enrolled and randomized by an interactive response technology (IRT) (1:1 ratio) to receive Toujeo or Tresiba. A total of 207 participants were screen failure mainly due to not meeting eligibility criteria.

Participant flow — Overall Study
MilestoneToujeoTresiba
Started172171
Completed164167
Not completed84
Withdrew: Withdrawal by subject22
Withdrew: Lack of efficacy10
Withdrew: Lost to follow-up42
Withdrew: Switch to insulin pump10

Outcome measures

PrimaryPercentage of Time of Glucose Concentration Within the Target Range of Greater Than or Equal to (>=) 70 to Less Than or Equal to (<=) 180 Milligrams Per Deciliter: Non-inferiority Analysis

The Continuous Glucose Monitoring (CGM) system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. Adjusted least square (LS) means and standard error (SE) were obtained using analysis of covariance (ANCOVA) model on data obtained from the multiple imputations during Week 10 to Week 12.

Time frame:
During Week 10 up to Week 12
Reported as:
Least squares mean · percentage of time
Percentage of Time of Glucose Concentration Within the Target Range of Greater Than or Equal to (>=) 70 to Less Than or Equal to (<=) 180 Milligrams Per Deciliter: Non-inferiority Analysis
percentage of timeToujeoTresiba
Percentage of Time of Glucose Concentration Within the Target Range of Greater Than or Equal to (>=) 70 to Less Than or Equal to (<=) 180 Milligrams Per Deciliter: Non-inferiority Analysis52.74 ± 0.85955.09 ± 0.893
Statistical analysis
  • Toujeo vs Tresiba · ANCOVA · p = 0.0067 (Threshold of significance at \<0.05.) · Least square mean difference: 3.16 · 95% CI 0.88 to 5.44This estimation parameter corresponds to the difference between Toujeo LS mean and 90% of Tresiba LS mean.
SecondaryGlucose Total Coefficient of Variation (CV%)

CV% was a measure of spread of variability relative to mean of population. For CGM glucose values, CV% was measure of glycemic variability across 20 days and calculated as ratio of standard deviation of glucose values to mean of glucose values. LS means and SE were obtained using ANCOVA model using fixed categorical effects of treatment groups (Toujeo, Tresiba), randomization stratum of screening HbA1c (\<8.0% versus \>=8.0%), and the continuous fixed covariate of Baseline value.

Time frame:
During Week 10 up to Week 12
Reported as:
Least squares mean · percentage of total CV
Glucose Total Coefficient of Variation (CV%)
percentage of total CVToujeoTresiba
Glucose Total Coefficient of Variation (CV%)39.91 ± 0.36041.22 ± 0.373
Statistical analysis
  • Toujeo vs Tresiba · ANCOVA · p = <0.0001 (Threshold of significance at \<0.05.) · Least square mean difference: -5.44 · 95% CI -6.50 to -4.38This estimation parameter corresponds to the difference between Toujeo LS mean and 110% of Tresiba LS mean.
SecondaryPercentage of Time of Glucose Concentration Within the Target Range of >=70 to <=180 Milligrams Per Deciliter: Superiority Analysis

The CGM system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. Adjusted LS means and SE were obtained using ANCOVA model on data obtained from the multiple imputations during Week 10 to Week 12.

Time frame:
During Week 10 up to Week 12
Reported as:
Least squares mean · percentage of time
Percentage of Time of Glucose Concentration Within the Target Range of >=70 to <=180 Milligrams Per Deciliter: Superiority Analysis
percentage of timeToujeoTresiba
Percentage of Time of Glucose Concentration Within the Target Range of >=70 to <=180 Milligrams Per Deciliter: Superiority Analysis52.74 ± 0.85955.09 ± 0.893
Statistical analysis
  • Toujeo vs Tresiba · ANCOVA · p = 0.0548 (Threshold of significance at \<0.05.) · Least square mean difference: -2.35 · 95% CI -4.75 to 0.05
SecondaryGlucose Within-day CV% and Between-day CV%

CV% was a measure of spread of variability relative to mean of population. For CGM glucose values, CV% was measure of glycemic variability across 20 days and calculated within day and between days as ratio of standard deviation of glucose values to mean of glucose values. LS mean and SE were obtained from ANCOVA model including fixed categorical effects of treatment groups (TOUJEO, TRESIBA), randomization stratum of screening HbA1c (\<8.0% versus \>=8.0%), and as well as, the continuous fixed covariate of Baseline value.

Time frame:
During Week 10 up to Week 12
Reported as:
Least squares mean · percentage of CV
Glucose Within-day CV% and Between-day CV%
percentage of CVToujeoTresiba
Within-day CV%33.48 ± 0.34234.37 ± 0.351
Between-day CV%17.23 ± 0.40418.08 ± 0.415
SecondaryChange From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 12

Change in HbA1c at Week 12 was analyzed using an ANCOVA model including the fixed categorical effects of treatment groups (Toujeo, Tresiba), and the continuous fixed covariate of Baseline HbA1c value.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 12
percentage of HbA1cToujeoTresiba
Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 12-0.75 ± 0.058-0.92 ± 0.057
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 12

Change in FPG was analyzed using an ANCOVA model including the fixed categorical effects of treatment groups (Toujeo, Tresiba) and the randomization stratum of HbA1c at screening (\<8.0%, \>=8.0%) and the continuous fixed covariate of Baseline FPG value.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · milligrams per deciliter
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12
milligrams per deciliterToujeoTresiba
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12-16.05 ± 5.455-34.55 ± 5.523
SecondaryPercentage of Time With Glucose Level <70 Milligrams Per Deciliter (All Time and During the Night)

The CGM system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. "All time" represent the time between 00.00 hour to 23.59 hours and "night" represent the time between 00.00 hour to 05.59 hours. LS means and SE were obtained using ANCOVA model using fixed categorical effects of treatment groups (Toujeo, Tresiba), randomization stratum of screening HbA1c (\<8.0% versus \>=8.0%), and the continuous fixed covariate of Baseline value.

Time frame:
During Week 10 up to Week 12
Reported as:
Least squares mean · percentage of time
Percentage of Time With Glucose Level <70 Milligrams Per Deciliter (All Time and During the Night)
percentage of timeToujeoTresiba
All time5.55 ± 0.3536.49 ± 0.362
Night6.32 ± 0.5116.26 ± 0.524
SecondaryMean Hours Per Day With Glucose Level <70 Milligrams Per Deciliter (All Time and During the Night)

"All time" represent the time between 00.00 hour to 23.59 hours and "night" represent the time between 00.00 hour to 05.59 hours. Mean hours per day with glucose level \<70 milligrams per deciliter during "all time" and only "during night" for the duration of Week 10 to Week 12 is reported in this outcome measure.

Time frame:
During Week 10 up to Week 12
Reported as:
Least squares mean · hours per day
Mean Hours Per Day With Glucose Level <70 Milligrams Per Deciliter (All Time and During the Night)
hours per dayToujeoTresiba
All time1.33 ± 0.0851.56 ± 0.087
Night0.38 ± 0.0310.38 ± 0.031
SecondaryPercentage of Time With Glucose Level >180 Milligrams Per Deciliter

The CGM system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. LS means and SE were obtained using ANCOVA model using fixed categorical effects of treatment groups (Toujeo, Tresiba), randomization stratum of screening HbA1c (\<8.0% versus \>=8.0%), and the continuous fixed covariate of Baseline value.

Time frame:
During Week 10 up to Week 12
Reported as:
Least squares mean · percentage of time
Percentage of Time With Glucose Level >180 Milligrams Per Deciliter
percentage of timeToujeoTresiba
Percentage of Time With Glucose Level >180 Milligrams Per Deciliter41.52 ± 0.97538.31 ± 1.002
SecondaryMean Hours Per Day With Glucose Level >180 Milligrams Per Deciliter

Mean hours per day with glucose level \>180 milligrams per deciliter for the duration of Week 10 to Week 12 is reported in this outcome measure.

Time frame:
During Week 10 up to Week 12
Reported as:
Least squares mean · hours per day
Mean Hours Per Day With Glucose Level >180 Milligrams Per Deciliter
hours per dayToujeoTresiba
Mean Hours Per Day With Glucose Level >180 Milligrams Per Deciliter9.96 ± 0.2349.19 ± 0.240
SecondaryNumber of Participants With at Least One Hypoglycemic Event During the On-treatment Period

Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions, because the participant was not capable of helping self. Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<3.9 millimoles per liter (mmol/L) (\<70 milligrams per deciliter). On-treatment period was defined as the time from the first injection of IMP (included) up to 2 days after the last injection of IMP.

Time frame:
From the first injection of IMP up to 2 days after the last injection of IMP (i.e., up to 86 days)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Hypoglycemic Event During the On-treatment Period
ParticipantsToujeoTresiba
Any hypoglycemia165166
Severe hypoglycemia810
Documented symptomatic hypoglycemia136134
SecondaryNumber of Hypoglycemic Events Per Participant Year During the On-treatment Period

Number of hypoglycemia events (any, severe and documented) per participant-year of exposure were reported. Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions, because the participant was not capable of helping self. Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<3.9 mmol/L (\<70 milligrams per deciliter). On-treatment period was defined as the time from the first injection of IMP (included) up to 2 days after the last injection of IMP. Total participant years = The sum of the duration of exposure for all participants, expressed in participant years.

Time frame:
From the first injection of IMP up to 2 days after the last injection of IMP (i.e., up to 86 days)
Reported as:
Number · events per participant-year
Number of Hypoglycemic Events Per Participant Year During the On-treatment Period
events per participant-yearToujeoTresiba
Any hypoglycemia109.4114.9
Severe hypoglycemia0.20.3
Documented symptomatic hypoglycemia67.166.9

Adverse events

Collected over From the first injection of IMP up to 2 days after the last injection of IMP (i.e., up to 86 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Toujeo0/172 (0%)7/172 (4.1%)0/172 (0%)
Tresiba0/171 (0%)8/171 (4.7%)0/171 (0%)
Most frequent serious events
Most frequent serious events
EventToujeoTresiba
HypoglycaemiaMetabolism and nutrition disorders0/1724/171
Hypoglycaemic UnconsciousnessNervous system disorders4/1722/171
Hypoglycaemic SeizureNervous system disorders2/1720/171
Diabetic KetoacidosisMetabolism and nutrition disorders0/1721/171
Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders0/1721/171
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders0/1721/171
Accidental OverdoseInjury, poisoning and procedural complications0/1721/171
Orthostatic IntoleranceNervous system disorders1/1720/171

Baseline characteristics

Analysis was performed on intent-to-treat (ITT) population which included all randomized participants (who signed the informed consent form and were allocated to a treatment group before the first investigational medicinal product \[IMP\] administration and recorded in the IRT database), irrespective of the treatment actually received and were analyzed according to the treatment group allocated by randomization.

Age, Continuous
Age, Continuous(years)ToujeoTresibaTotal
Mean42.9 ± 13.5342.8 ± 13.0542.8 ± 13.28
Sex: Female, Male
Sex: Female, Male(Participants)ToujeoTresibaTotal
Female8674160
Male8697183
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)ToujeoTresibaTotal
Count of participants——0
08

Study locations

7 sites
  • United States
    Dallas, Texas 75000, United States
  • Investigational site BRAZIL
    Brazil, Brazil
  • Investigational site Germany
    Germany, Germany
  • Investigational site Hungary
    Hungary, Hungary
  • Investigational site Netherlands
    Netherlands, Netherlands
  • Investigational site Turkey
    Turkey, Turkey
  • Investigational site United Kingdom
    United Kingdom, United Kingdom
09

References and documents

Publications

  • Battelino T, Bosnyak Z, Danne T, Mukherjee B, Edelman S, Pilorget V, Choudhary P, Renard E, Bergenstal R. InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design. Diabetes Ther. 2020 Apr;11(4):1017-1027. doi: 10.1007/s13300-020-00781-6. Epub 2020 Feb 25. Erratum In: Diabetes Ther. 2020 Jul;11(7):1607-1608. doi: 10.1007/s13300-020-00820-2. Diabetes Ther. 2020 Aug;11(8):1907-1908. doi: 10.1007/s13300-020-00853-7. PubMed 32100192 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Sep 2021, 23 months.

Results were first posted in Nov 2022, 1 year 1 month after primary completion.

Of 74 phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2019
First posted
Aug 30, 2019
StartActual
Oct 9, 2019
Primary completionActual
Sep 16, 2021
CompletionActual
Sep 16, 2021
Results first posted
Nov 14, 2022
Last update
Nov 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04075513
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 30, 2019
Start date
Oct 9, 2019
Primary completion
Sep 16, 2021
Completion
Sep 16, 2021
Results posted
Nov 14, 2022
Last update
Nov 14, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion